Before the CDC guidelines, 45% of the patients were prescribed opioids, but that fell to 34% after the guidelines.
The nation’s reckoning with the opioid epidemic brought responses across the healthcare landscape, from health plan monitoring that involved both physicians and pharmacists, to crackdowns on physicians who wrote too many questionable prescriptions for pain medication.
One area of concern involved the emergency department (ED), where patients may be prescribed opioids for after showing up complaining of musculoskeletal pain, perhaps caused by an injury. Guidelines issued by the CDC in March 2016 noted the role that prescribing for acute pain could play in eventual opioid abuse: the recommendations stated that three days’ worth of medication was often sufficient, and more than seven days of medication was rarely needed.
A practice brief published online for an upcoming issue of the Journal of Public Health Management and Practice shows the immediate effect of the CDC guidelines on opioid prescribing. Data from just over 1,000 patients were culled from electronic health records, covering both the months before and the period immediately after the guidelines were issued. The records involved patients treated for lower back pain at a community hospital emergency department operated by Penn Medicine in New Jersey.
Before the guidelines, 45% of the patients were prescribed opioids, but that fell to 34% after the guidelines. Of those who received an opioid prescription, there was a 6% reduction in the number of patients who received a prescription for more than five days, from 14% to 8%.
Not long after the study period ended, New Jersey adopted a law limiting the first prescription for opioids to five days in most cases, which at the time was the strictest in the country. The authors said the effects of this law warranted further study.
The ongoing multifaceted approach should continue, the authors wrote.
“The state prescription monitoring programs help physicians and pharmacists to be vigilant and look for red flag signs of opioid misuse,” they said. “Further studies are needed for implementing these opioid-prescribing guidelines in various health care settings and for other pain conditions.”
Hospitals relieved by Johnson & Johnson reversal on rebate plan, but 340B battle goes on
Published: October 3rd 2024 | Updated: October 3rd 2024The drug giant is abandoning a plan to require hospitals to submit requests for rebates in the 340B drug discount program. The government threatened to remove the company’s drugs from Medicare and Medicaid programs.